Vasomotor Symptoms Associated With Menopausal Disorder — Patent Landscape
1
Approved drugs
101
Active US patents
37/100
Avg vulnerability
—
Annual revenue covered
Originators in Vasomotor Symptoms Associated With Menopausal Disorder
Cliff calendar — next 15 years
11
28
1
29
5
30
76
32
2
33
2
34
2
37
1
38
Approved drugs ranked by patent estate
| Drug | Originator | Active patents | Avg vuln | Revenue | First cliff |
|---|---|---|---|---|---|
|
Estrace
ESTRADIOL
|
Pfizer | 101 | 37 | — | 2028-07-10 |
Most attackable patents
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 9730900 | Estrace | method of use | 58 | 2028-07-10 |
| 9730900 | Estrace | method of use | 58 | 2028-07-10 |
| 9730900 | Estrace | method of use | 58 | 2028-07-10 |
| 9730900 | Estrace | method of use | 58 | 2028-07-10 |
| 9730900 | Estrace | method of use | 58 | 2028-07-10 |
| 11957684 | Estrace | method of use | 58 | 2037-09-29 |
| 11793819 | Estrace | method of use | 53 | 2032-11-21 |
| 11793819 | Estrace | method of use | 53 | 2032-11-21 |
| 11241445 | Estrace | method of use | 53 | 2032-11-21 |
| 11241445 | Estrace | method of use | 53 | 2032-11-21 |
Strongest defences
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 11795178 | Estrace | composition of matter | 0 | 2033-09-27 |
| 12325714 | Estrace | composition of matter | 0 | 2033-09-27 |
| 11865179 | Estrace | composition of matter | 0 | 2032-11-21 |
| 11865179 | Estrace | composition of matter | 0 | 2032-11-21 |
| 8231906 | Estrace | composition of matter | 0 | 2030-07-04 |
| 8231906 | Estrace | composition of matter | 0 | 2030-07-04 |
| 8231906 | Estrace | composition of matter | 0 | 2030-07-04 |
| 8231906 | Estrace | composition of matter | 0 | 2030-07-04 |
| 8231906 | Estrace | composition of matter | 0 | 2030-07-04 |
| 7300935 | Estrace | composition of matter | 0 | 2029-01-28 |
Related
- Vasomotor Symptoms Associated With Menopausal Disorder — full disease profile
- AI Patent Landscape Report — type "vasomotor symptoms associated with menopausal disorder" for an AI exec memo
- Company Patent Rankings
- Biosimilar Opportunity Scanner